Bull or Bear, Seeking Alpha is there
Markets change, but our community always has the latest news, in-depth analysis, and powerful stock ratings.

By creating an account using any of the options above, you agree to the Terms of Use & Privacy Policy

Bull or Bear, Seeking Alpha is there
Markets change, but our community always has the latest news, in-depth analysis, and powerful stock ratings.

Analysis

All Analysis
AI Tech
Basic Materials
Biotech
Bonds
Closed End Funds
Commodities
Communication Services
Consumer
Consumer Staples
Cryptocurrency
Dividend Ideas
Dividend Quick Picks
Dividend Strategy
Dividends
Editors' Picks
Electric Vehicles
Energy
ETF Analysis
ETFs and Funds
Financial Advisor
Financials
Fixed Income
Forex
Gold & Precious Metals
Growth
Healthcare
Industrial
Interest Rates
Investing Strategy
IPOs
Long Ideas
Magnificent 7
Market Outlook
Micro-Caps
Mutual Funds
Podcast
Portfolio Strategy
Quick Picks & Lists
Real Estate
REITs
Retirement
Small-Caps
Stock Ideas
Tech
Trending Analysis
U.S. Economy
Undercovered Stocks
Utilities
Value
Weight Loss

Healthcare, Biotech & Pharmaceutical Stock News and Analysis

UnitedHealth: Federal Budget Cuts Threaten Growth

UNHJoseph ParrishToday, 2:22 AM3 Comments

Henry Schein: An Industry Leader That Offers Some Upside From Here

HSICDaniel JonesYesterday, 5:57 PM

Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy

AUTLGalzus ResearchYesterday, 10:21 AM3 Comments

Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity

KURAGalzus ResearchYesterday, 10:12 AM

Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness

SRPTStephen AyersYesterday, 8:15 AM2 Comments

Pfizer Remains A Good Pick For Dividend Investors

PFE, PFE:CADaniel SchönbergerYesterday, 7:34 AM3 Comments

Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide

PRAXTerry ChrisomalisYesterday, 7:30 AM

Viatris: A Unique S&P 500 'Fallen Angel' With Intriguing Potential

VTRSSungarden Investment PublishingYesterday, 7:12 AM12 Comments

Monopar Therapeutics: Strong Data, But There Are Risks

MNPRAvisol Capital PartnersYesterday, 4:54 AM

Spyre Therapeutics: Targeting The Future Of IBD Treatment

SYREEquity EagleYesterday, 4:51 AM1 Comment

My Sleep Apnea Has Led Me To Profits With AdaptHealth

AHCOJeffrey Fischer, CFAYesterday, 3:47 AM

Checkpoint Therapeutics: Pivoting From Approval To Gutsy Next Shot On Goal

CKPTGalzus ResearchMon, Mar. 0318 Comments

TransMedics: Aggressive Guidance Largely Ignored By The Market

TMDXRichard DurantMon, Mar. 034 Comments

High Tide Has A Killer Business Model

HITI, HITI:CABlake DownerMon, Mar. 0314 Comments

Corvus Pharmaceuticals: Small Market, Many Competitors, Low Cash Balance

CRVSAvisol Capital PartnersMon, Mar. 03

Why I Took Profits On CVS

CVS, CVS:CAYiannis ZourmpanosMon, Mar. 033 Comments

Collegium Pharmaceutical: Checking The Boxes

COLLBret JensenMon, Mar. 031 Comment

CARGO Therapeutics: A Gutted CAR T Player Trying To Find New Direction

CRGXGalzus ResearchMon, Mar. 03

Lifecore Biomedical: We Are Not Playing To Make 5% Or 10% Here

LFCRFund Letter Stock IdeasMon, Mar. 031 Comment

Prothena Corporation: Multiple Failures Make It Risky

PRTAAvisol Capital PartnersMon, Mar. 032 Comments

Semler: It Is Best To Wait Until The Dust Settles With Bitcoin, Medicare, And Pending QuantaFlo Clearance

SMLRDaniel MelladoMon, Mar. 031 Comment

Hims & Hers: A Generational Dip-Buying Opportunity

HIMSRiyado SofianSun, Mar. 0220 Comments

Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window

VRDNAvisol Capital PartnersSun, Mar. 022 Comments

A Volatile Share Price Masks Some Of The Progress At Inogen

INGNStephen SimpsonSat, Mar. 011 Comment

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025

HROW, HROWLRational ExpectationsSat, Mar. 0117 Comments

CooperCompanies: A Somewhat Less Demanding Valuation, But Some Added Growth Concerns

COOStephen SimpsonSat, Mar. 01

Tyra Biosciences: FGFR1/2 Driven AE Data Spooked The Market

TYRAAvisol Capital PartnersSat, Mar. 01

Agilent Technologies: Recent Price Weakness Makes This Stock A Buy

ADividend Yield TheoristSat, Mar. 01

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib

NAMSTejo Strategy InvestingFri, Feb. 283 Comments

Compass Pathways: Betting On The Future Of Psilocybin Therapy

CMPSEquity EagleFri, Feb. 28

Repeated Disappointments On Growth And Margins Leaves Conmed Even Deeper In The Doghouse

CNMDStephen SimpsonFri, Feb. 28

BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025

ONCBrendan O'BoyleFri, Feb. 284 Comments

NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution

NAMSEquity EagleFri, Feb. 282 Comments

Verve Therapeutics: Key Data Catalysts, Major Share Price Volatility In Play In Q2

VERVEdmund InghamFri, Feb. 281 Comment

12 3 4 5 Next

Investing Groups

Portfolios

Find & Compare

Subscriptions

Analysis

Healthcare, Biotech & Pharmaceutical Stock News and Analysis